Table 6.
Literature review of the outcomes of inoperable stage I-IV endometrial cancer patients receiving radiotherapy.
| Authors | Method | Number | Stage | Applicator | Local recurrence (%) | OS (%) | Late toxicity (%) |
|---|---|---|---|---|---|---|---|
| Inciura, et al. (16) | HDRB +/- EBRT | 29 | I–III | Three-channel | 17.2 (4/29) | 48.3 (5 y) | 13.8 (4/29) |
| Rouanet, et al. (24) | LDRB +/- EBRT | 147 | I–III | — | 24 (36/147) | 58.4 (5 y) | 11.7 |
| Knocke, et al. (9) | HDRB +/- EBRT | 280 | I–III | One-channel | 22.9 (64/280) | 52.7 (5 y) | 23.9 |
| Churn and Jone (8) | HDRB +/- EBRT | 37 | I-II | One-channel | 16 (6/37) | 68.4 (5 y) | — |
| III–IV | 33 (5 y) | ||||||
| Current study | NBT +/- EBRT | 31 | I–III | Two-channel | 19.4 (6/31) | 51.6 (5 y) | 12.9 (4/31) |
OS: overall survival; LDRB: low-dose-rate brachytherapy; HDRB: high-dose-rate brachytherapy; EBRT: external beam radiation therapy; NBT: neutron brachytherapy.